What is Nilogen Oncosystems?
Nilogen Oncosystems is at the forefront of oncology innovation, specializing in the development of advanced 3D cancer models. Utilizing its proprietary 3D-EXplore technology, the company meticulously captures the intricate heterogeneity of tumors directly from fresh human tissue. This sophisticated approach provides unparalleled insights for a range of oncology applications, including crucial biomarker discovery, the advancement of cell therapies, and the complex field of immuno-oncology. By delivering comprehensive analyses, Nilogen Oncosystems empowers clients in the pharmaceutical and biotechnology sectors to enhance their drug development pipelines and make more informed decisions, ultimately aiming to improve patient outcomes through a deeper understanding of therapeutic responses and tumor microenvironments.
How much funding has Nilogen Oncosystems raised?
Nilogen Oncosystems has raised a total of $92K across 1 funding round:
Debt
$92K
Debt (2021): $92K with participation from PPP
Key Investors in Nilogen Oncosystems
PPP
Public-Private Partnership
What's next for Nilogen Oncosystems?
With the recent influx of substantial expansion capital, Nilogen Oncosystems is poised for significant scaling and further technological advancement. The company's strategic focus will likely involve broadening its service offerings, enhancing its 3D-EXplore platform's capabilities, and potentially expanding its market reach within the global oncology research landscape. This investment is expected to accelerate the company's mission to refine cancer treatment strategies and expedite the development of novel therapeutics by providing critical data and analytical support to its partners.
See full Nilogen Oncosystems company page
